News Releases
New data shows ProMark accurately predicts aggressive prostate cancer, pathology outcomes
Today, for the first time, Metamark presents results from the clinical validation study that showed ProMark™, the first and only proteomic-based imaging biopsy test, achieved its primary endpoint.
Nasal Gel for Low Testosterone Gets FDA Approval
Trimel Pharmaceuticals Corporation (TSX: TRL) announced today that the United States Food and Drug Administration (FDA) has approved Natesto™ (testosterone), formerly CompleoTRT™, to treat men with low testosterone.
Tefina Increased Number of Orgasms for Women
Trimel Pharmaceuticals Corporation (TSX: TRL) announced today top-line results of its Phase II clinical trial evaluating the efficacy and safety of Tefina™, a “use-as-required” testosterone nasal gel for the treatment of Female Orgasmic Disorder (FOD).
FDA Approves New Asthma Inhaler with Dose Counter
Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved the use of QVAR® (beclomethasone dipropionate HFA) with a dose counter for the ongoing treatment of asthma as a preventative therapy in patients 5 years of age and older.
FDA Approves New COPD Treatment
The FDA has approved a new treatment to help COPD patients breathe easier.
FDA Approves New Leukemia Treatment
The FDA has given some leukemia patients a new treatment option.
FDA Approves New Rx for Grass Pollen-Induced Allergic Rhinitis
The FDA has approved a new medication for those with symptoms caused by grass pollen allergy.
FDA Approves Pradaxa for Clotting Disorders
US regulators have approved a medication to treat and reduce two dangerous clotting disorders.
Greer Announces FDA Approval of Oralair for Grass Pollen Allergy
The FDA has approved a new medication to treat grass pollen allergies.
FDA Okays Headband for Migraines
Today, the U.S. Food and Drug Administration allowed marketing of the first device as a preventative treatment for migraine headaches.